Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06046833 · ClinicalTrials.gov registry record · NA
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
A NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1, sponsored by Samita Garg.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06046833: Recruiting NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1, sponsored by Samita Garg.
NCT06046833 is a NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1 that is actively recruiting participants, run by Samita Garg. The registered enrollment target is 50 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06046833, a NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1, is actively recruiting participants, sponsored by Samita Garg.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
A pilot study to evaluate and compare glucose metrics using a real-time continuous glucose monitor (FreeStyle Libre 3 sensor) between patients with diabetes and gastroparesis and those with diabetes without gastroparesis.
Primary Outcome
Percentage of time spent per day (and estimated actual amount of time in hours or minutes per day) in target glucose range 70-180 mg/dL.
Conditions Studied
Interventions
- DEVICE FreeStyle Libre 3 continuous glucose monitoring sensor
- OTHER Nutritional drink
Study Locations (1)
Ohio
- Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-01-08 |
| Est. Completion | 2026-03 |
| Phase | NA |
What NCT06046833 shows while recruiting
NCT06046833 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which FreeStyle Libre 3 continuous glucose monitoring sensor is the first listed.
NCT06046833 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06046833 about?
NCT06046833 is a clinical study titled "Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes". A pilot study to evaluate and compare glucose metrics using a real-time continuous glucose monitor (FreeStyle Libre 3 sensor) between patients with diabetes and gastroparesis and those with diabetes without gastroparesis.
What is the current status of trial NCT06046833?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2024-01-08. Estimated completion is 2026-03.
What conditions does trial NCT06046833 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Gastroparesis With Diabetes Mellitus.
What interventions are being tested in trial NCT06046833?
The interventions under investigation include: FreeStyle Libre 3 continuous glucose monitoring sensor (DEVICE), Nutritional drink (OTHER).
Who is sponsoring clinical trial NCT06046833?
This trial is sponsored by Samita Garg, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06046833 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06046833's enrollment target sits among peer trials
50 259th of 348 higher than 86 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
-
Phenotyping Genetic Risk for Type 2 Diabetes
RECRUITING · NA
-
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
RECRUITING · NA
-
Efficacy of Using Mobile Health Applications for Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI